You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 11,452,720

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,452,720

Title:	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Abstract:	Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
Inventor(s):	Zhe Li, Stephan D. PARENT, Travis HOUSTON
Assignee:	Global Blood Therapeutics Inc
Application Number:	US16/923,498
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,452,720
Patent Claims:	1. A method for treating sickle cell disease, comprising administering to a patient in need thereof: a composition comprising a crystalline ansolvate of Compound 1: characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), wherein the composition is substantially free of other ansolvate polymorphs of Compound 1; and another active agent. 2. The method of claim 1, wherein the composition and the active agent are co-administered. 3. The method of claim 1, wherein the composition and the active agent are administered in a single pharmaceutical composition. 4. The method of claim 1, wherein the composition and the active agent are administered by the same route of administration. 5. The method of claim 1, wherein the composition and the active agent are administered by different routes of administration. 6. The method of claim 1, wherein the composition is administered orally. 7. The method of claim 4, wherein the route of administration is oral. 8. The method of claim 1, wherein the composition is substantially free of solvated polymorphs of Compound 1. 9. The method of claim 1, wherein the composition comprises less than 10 mole % of amorphous forms of Compound 1. 10. A pharmaceutical composition comprising: a composition comprising a crystalline ansolvate of Compound 1: characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), wherein the composition is substantially free of other ansolvate polymorphs of Compound 1; and another active agent. 11. The pharmaceutical composition of claim 10, wherein the crystalline ansolvate of Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5. 12. The pharmaceutical composition of claim 10, wherein the crystalline ansolvate of Compound 1 is characterized by an endothermic peak at 97±2° C. as measured by differential scanning calorimetry. 13. The pharmaceutical composition of claim 10, wherein the composition is substantially free of solvated polymorphs of Compound 1. 14. The pharmaceutical composition of claim 10, wherein the composition comprises less than 10 mole % of amorphous forms of Compound 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.